All Updates

All Updates

icon
Filter
Partnerships
Oncodesign Precision Medicine and Navigo Proteins partner for systemic radiotheranostic agents development
Precision Medicine
May 15, 2024
This week:
M&A
Funding
TravelPerk raises USD 135 million in debt funding for expansion; acquires AmTrav
Travel Tech
Yesterday
Product updates
Apple announces Apple Pay Later shutdown
Buy Now, Pay Later
Jun 17, 2024
Management news
Velo3D appoints Brad Kreger as permanent CEO
Additive Manufacturing
Jun 17, 2024
Partnerships
Perplexity partners with SoftBank for AI search engine promotion in Japan
Generative AI Applications
Jun 17, 2024
Product updates
Runway launches Gen-3 Alpha for generating video clips
Generative AI Applications
Jun 17, 2024
Product updates
Adobe integrates Firefly into Acrobat with chat support across multiple documents in Acrobat AI Assistant
Generative AI Applications
Jun 17, 2024
Funding
Amplify Life raises USD 20 million in Series B to expand product suite
InsurTech: Personal Lines
Jun 17, 2024
Funding
Tinybird raises USD 30 million in Series B funding to improve real-time data analytics platform
Data Infrastructure & Analytics
Jun 17, 2024
Partnerships
The EVERY Company collaborates with Grupo Palacios to develop hen-less omelets
Plant-based Dairy & Egg
Jun 17, 2024
Partnerships
Believer Meats partners with AGWA to propel cultivated meat industry in MENA region
Cell-cultured Meat
Jun 17, 2024
Precision Medicine

Precision Medicine

May 15, 2024

Oncodesign Precision Medicine and Navigo Proteins partner for systemic radiotheranostic agents development

Partnerships

  • Navigo Proteins and Oncodesign Precision Medicine have entered a partnership focusing on the advancement of novel systemic radiotheranostic agents used in cancer treatment.

  • The partnership will leverage OPM's technologies and Navigo's proprietary Affilin platform to develop new treatments for resistant and metastatic cancers. The aim is to create radiotheranostic agents that can detect and destroy tumor cells, a method that's been clinically successful in treating specific types of cancers. The partnership will initially focus on two targets in oncology and develop molecules to the stage of drug candidates. The companies also aim to expand the partnership to additional targets. 

  • Headquartered in Germany, Navigo Proteins is a biotechnology company specializing in protein engineering. Its focus is on developing precision affinity ligands and biotherapeutics. Navigo Proteins uses its proprietary platforms, Precision Capturing and Precision Targeting, to create custom affinity chromatography solutions and novel biotherapeutics, respectively.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.